A pinch of salt - A podcast by ERA

One of the most cheeky subjects in Nephrology is the diagnostic and therapeutic interventions on the nutritional status of CKD patients.

It is cheeky because when it is not good it may kill the patient and also because it is one of the typical subjects that we « think » we know » but when we scratch a little bit we realise there are huge undiscovered avenues to explore.

In order to know a bit more about it, check on the new episode of the ERA podcast "A pinch of Salt" concerning Nutrition in CKD with prof Giorgina Piccoli, Chair of the European Renal Nutrition (ERN) Working Group. 

There’s a new kid on the block and he can bang up cancer cells very effectively, but, he doesn’t like to discriminate and won’t think a bit about roughing up the kidney as well. This kid has a fancy name – immune checkpoint inhibitor. Oncologists are raving about it, but nephrologists are freaking out about it. How do we solve this mess? Can cancer patients keep receiving these medications even if they have renal adverse events? And what about transplant patients? If you’ve wondered about this yourself, then you’re in luck because we’ll be asking these and similar relevant questions to Dr Sandra Herrmann, a well-known expert in the field of onco-nephrology. 

Let's share a secret! After a very long period in the desert of stagnating therapeutic options in nephrology, we are living lately one of the most exciting periods of its history. A large number of new treatments and drugs are already in practice or planned to be introduced to our therapeutic algorithms in the years to come. The volume of information arriving every day is huge. Diabetic nephropathy is a case study of this evolution and, rightfully so, a target of a large number of these new therapeutic options. So if you are a little bit lost with this tsunami of information about diabetic nephropathy, if you are a little bit confused about the large number of actual and future treatment options stay with us! In this ERA podcast, we’ll discuss diabetic Nephropathy with Professor Morales an eminent figure on the subject.

Kidney stones are a most unpleasant disease. It’s also a dangerous disease, a disease that may cause CKD, a disease that can be linked to a higher cardiovascular risk, and even a potentially deadly disease with concomitant urinary tract infection. Should we, as nephrologists, be more involved in the treatment of these patients? How should we assess and treat patients with recurrent kidney stones? Does it really matter? If you’re thinking about these things, you’re on the right track. Learn all the tricks of the trade by listening to David Goldfarb on the Kidney Stone podcast.